156 related articles for article (PubMed ID: 37816743)
1. Vaccination with a replication-defective cytomegalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection.
Valencia SM; Rochat E; Harnois MJ; Dennis M; Webster HS; Hora B; Kumar A; Wang HS; Li L; Freed D; Zhang N; An Z; Wang D; Permar SR
NPJ Vaccines; 2023 Oct; 8(1):154. PubMed ID: 37816743
[TBL] [Abstract][Full Text] [Related]
2. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
3. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
[TBL] [Abstract][Full Text] [Related]
4. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
[TBL] [Abstract][Full Text] [Related]
5. Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection.
Goodwin ML; Webster HS; Wang HY; Jenks JA; Nelson CS; Tu JJ; Mangold JF; Valencia S; Pollara J; Edwards W; McLellan JS; Wrapp D; Fu TM; Zhang N; Freed DC; Wang D; An Z; Permar SR
Virology; 2020 Sep; 548():182-191. PubMed ID: 32838941
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
Webster H; Valencia S; Kumar A; Chan C; Dennis M; Roark H; Woods A; John S; Carfi A; Permar SR
Vaccine; 2021 Sep; 39(38):5358-5367. PubMed ID: 34393017
[TBL] [Abstract][Full Text] [Related]
7. Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model.
Valencia S; Gill RB; Dowdell KC; Wang Y; Hornung R; Bowman JJ; Lacayo JC; Cohen JI
Vaccine; 2019 Jan; 37(2):333-342. PubMed ID: 30522906
[TBL] [Abstract][Full Text] [Related]
8. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
9. Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.
Wang HY; Li L; Nelson CS; Barfield R; Valencia S; Chan C; Muramatsu H; Lin PJC; Pardi N; An Z; Weissman D; Permar SR
NPJ Vaccines; 2024 Feb; 9(1):38. PubMed ID: 38378950
[TBL] [Abstract][Full Text] [Related]
10. A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera.
Gomes AC; Baraniak IA; McIntosh MR; Sodi I; Langstone T; Siddiqui S; Atkinson C; McLean GR; Griffiths PD; Reeves MB
J Gen Virol; 2023 Jun; 104(6):. PubMed ID: 37310000
[TBL] [Abstract][Full Text] [Related]
11. Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.
Wiegers AK; Sticht H; Winkler TH; Britt WJ; Mach M
J Virol; 2015 Jan; 89(1):361-72. PubMed ID: 25320309
[TBL] [Abstract][Full Text] [Related]
12. Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.
Reuter N; Kropff B; Schneiderbanger JK; Alt M; Krawczyk A; Sinzger C; Winkler TH; Britt WJ; Mach M; Thomas M
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641474
[TBL] [Abstract][Full Text] [Related]
13. Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.
Jenks JA; Nelson CS; Roark HK; Goodwin ML; Pass RF; Bernstein DI; Walter EB; Edwards KM; Wang D; Fu TM; An Z; Chan C; Permar SR
Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148624
[TBL] [Abstract][Full Text] [Related]
14. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
[TBL] [Abstract][Full Text] [Related]
15. A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial.
Li L; Freed DC; Liu Y; Li F; Barrett DF; Xiong W; Ye X; Adler SP; Rupp RE; Wang D; Zhang N; Fu TM; An Z
NPJ Vaccines; 2021 Jun; 6(1):79. PubMed ID: 34078915
[TBL] [Abstract][Full Text] [Related]
16. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.
Pötzsch S; Spindler N; Wiegers AK; Fisch T; Rücker P; Sticht H; Grieb N; Baroti T; Weisel F; Stamminger T; Martin-Parras L; Mach M; Winkler TH
PLoS Pathog; 2011 Aug; 7(8):e1002172. PubMed ID: 21852946
[TBL] [Abstract][Full Text] [Related]
17. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
[TBL] [Abstract][Full Text] [Related]
18. Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination.
Li F; Freed DC; Tang A; Rustandi RR; Troutman MC; Espeseth AS; Zhang N; An Z; McVoy M; Zhu H; Ha S; Wang D; Adler SP; Fu TM
NPJ Vaccines; 2017; 2():36. PubMed ID: 29263890
[TBL] [Abstract][Full Text] [Related]
19. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
20. The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread.
Gomes AC; Baraniak IA; Lankina A; Moulder Z; Holenya P; Atkinson C; Tang G; Mahungu T; Kern F; Griffiths PD; Reeves MB
Nat Commun; 2023 Feb; 14(1):1041. PubMed ID: 36823200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]